
Sign up to save your podcasts
Or


In this episode, Dr. Makoto Mori, Associate Editor at JACC and Assistant Professor of Cardiac Surgery at Yale, interviews Dr. Paul Sorajja, lead author of the SUMMIT MAC Trial. They discuss the groundbreaking results of this study, which explores the use of the Tendyne transcatheter mitral valve replacement (TMVR) device in patients with severe mitral annular calcification (MAC)—a group traditionally challenging to treat surgically. Dr. Sorajja shares key findings, including high technical success rates, effective screening protocols, and significant improvements in patient outcomes. This conversation highlights a major advancement in structural heart disease treatment and its implications for clinical practice.
By American College of CardiologyIn this episode, Dr. Makoto Mori, Associate Editor at JACC and Assistant Professor of Cardiac Surgery at Yale, interviews Dr. Paul Sorajja, lead author of the SUMMIT MAC Trial. They discuss the groundbreaking results of this study, which explores the use of the Tendyne transcatheter mitral valve replacement (TMVR) device in patients with severe mitral annular calcification (MAC)—a group traditionally challenging to treat surgically. Dr. Sorajja shares key findings, including high technical success rates, effective screening protocols, and significant improvements in patient outcomes. This conversation highlights a major advancement in structural heart disease treatment and its implications for clinical practice.